Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data.

As a new approach to predicting in vivo drug metabolism in humans, scaling of in vivo metabolic clearance from in vitro data obtained using human liver microsomes or hepatocytes is described in this review, based on the large number of literature data. Successful predictions were obtained for verapamil, loxtidine (lavoltidine), diazepam, lidocaine, phenacetin and some other compounds where CLint,in vitro is comparable with CLint,in vivo. On the other hand, for some metabolic reactions, differences in CLint,in vitro and CLint,in vivo greater than 5-fold were observed. The following factors are considered to be the cause of the differences: (1) metabolism in tissues other than liver, (2) incorrect assumption of rapid equilibrium of drugs between blood and hepatocytes, (3) presence of active transport through the sinusoidal membrane, and (4) interindividual variability. Furthermore, the possibility of predicting in vivo drug metabolic clearance from results obtained using a recombinant system of human P450 isozyme was described for a model compound, YM796, where the predicted metabolic clearances obtained from the recombinant system, taking account of the content of the P450 isozyme CYP3A4 in the human microsomes, were comparable with the observed clearances using human liver microsomes containing different amounts of CYP3A4. Even in the case where the first-pass metabolism exhibits nonlinearity, it appears to be possible to predict in vivo metabolic clearance from in vitro metabolic data.

[1]  G. de Sousa,et al.  Interspecies variability in mitoxantrone metabolism using primary cultures of hepatocytes isolated from rat, rabbit and humans. , 1991, Biochemical pharmacology.

[2]  G L Amidon,et al.  The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids. , 1990, Gastroenterology.

[3]  M. Gibaldi,et al.  The warfarin‐sulfinpyrazone interaction: stereochemical considerations , 1986, Clinical pharmacology and therapeutics.

[4]  J. Cannon,et al.  Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine (ARA-C) deamination in several species. , 1973, Biochemical pharmacology.

[5]  J. Lin,et al.  Kinetic studies on the deethylation of ethoxybenzamide. A comparative study with isolated hepatocytes and liver microsomes of rat. , 1980, Biochemical pharmacology.

[6]  D. Greenblatt,et al.  Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. , 1993, Pharmacology.

[7]  J. Caldwell,et al.  A metabolic and pharmacokinetic comparison of theophylline and aminophylline (theophylline ethylenediamine) , 1981, The Journal of pharmacy and pharmacology.

[8]  G R Wilkinson,et al.  Clearance approaches in pharmacology. , 1987, Pharmacological reviews.

[9]  J. Lin,et al.  Species similarities and differences in pharmacokinetics. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[10]  R. Chenery,et al.  Comparative drug metabolism of diazepam in hepatocytes isolated from man, rat, monkey and dog. , 1989, Biochemical pharmacology.

[11]  B. Dvorchik,et al.  Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine , 1975, Clinical pharmacology and therapeutics.

[12]  M. Gibaldi,et al.  Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. , 1989, Drug metabolism and disposition: the biological fate of chemicals.

[13]  W. L. Nelson,et al.  Inhibition of the enantioselective oxidative metabolism of metoprolol by verapamil in human liver microsomes. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[14]  P. Beaune,et al.  Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. , 1991, Biochemical pharmacology.

[15]  P. Meffin,et al.  Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide , 1977, Clinical pharmacology and therapeutics.

[16]  T. Shimada,et al.  Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450s. , 1990, The Journal of pharmacology and experimental therapeutics.

[17]  K. Bischoff,et al.  Methotrexate pharmacokinetics. , 1971, Journal of pharmaceutical sciences.

[18]  R. Elofsson,et al.  Binding of two adrenergic beta-receptor antagonists, alprenolol and H 93-26, to human serum proteins. , 1974, Acta pharmaceutica Suecica.

[19]  P. Robinson,et al.  Hepatic elimination of flowing substrates: the distributed model. , 1978, Journal of theoretical biology.

[20]  L. Bass,et al.  Physiologically based models and strategic experiments in hepatic pharmacology. , 1988, Biochemical pharmacology.

[21]  J. Miners,et al.  Lidocaine disposition—Sex differences and effects of cimetidine , 1984, Clinical pharmacology and therapeutics.

[22]  M. Eichelbaum,et al.  Physiological disposition of verapamil in man. , 1976, Cardiovascular research.

[23]  M. Bayliss,et al.  Prediction of intrinsic clearance of loxtidine from kinetic studies in rat, dog and human hepatocytes. , 1990, Biochemical Society transactions.

[24]  R. Ogilvie,et al.  Pharmacokinetics of intravenous theophylline , 1973, Clinical pharmacology and therapeutics.

[25]  M. Rowland,et al.  Models of hepatic drug clearance: discrimination between the ‘well stirred’ and ‘parallel‐tube’ models , 1983, The Journal of pharmacy and pharmacology.

[26]  M. Eichelbaum,et al.  Stereoselective protein binding of verapamil enantiomers. , 1988, Biochemical pharmacology.

[27]  M. Eichelbaum,et al.  Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects. , 1992, The Journal of pharmacology and experimental therapeutics.

[28]  J. Timbrell,et al.  Factors affecting the metabolism of phenacetin. I. Influence of dose, chronic dosage, route of administration and species on the metabolism of (1-14C-acetyl)phenacetin. , 1974, Xenobiotica; the fate of foreign compounds in biological systems.

[29]  Y. Sugiyama,et al.  Applications and prospects for physiologically based pharmacokinetic (PB-PK) models involving pharmaceutical agents. , 1995, Toxicology letters.

[30]  M. Rowland,et al.  Correlation between in‐vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model , 1986, The Journal of pharmacy and pharmacology.

[31]  L. Benet,et al.  Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction , 1992, Clinical pharmacology and therapeutics.

[32]  J. Clements,et al.  Absorption, distribution and elimination of mexiletine. , 1977, Postgraduate medical journal.

[33]  T. Ishizaki,et al.  Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese , 1989, Clinical pharmacology and therapeutics.

[34]  T Iwatsubo,et al.  PREDICTION OF IN VIVO DRUG DISPOSITION FROM IN VITRO DATA BASED ON PHYSIOLOGICAL PHARMACOKINETICS , 1996, Biopharmaceutics & drug disposition.

[35]  R. Ogilvie,et al.  Theophylline disposition in patients with hepatic cirrhosis. , 1977, The New England journal of medicine.

[36]  R. Kato,et al.  Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. , 1993, Pharmacogenetics.

[37]  J B Houston,et al.  Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.

[38]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[39]  J. Turgeon,et al.  Erythrocyte and serum distribution of mexiletine in man. , 1987, Biopharmaceutics & drug disposition.

[40]  B. Hoener,et al.  Predicting the hepatic clearance of xenobiotics in humans from in vitro data , 1994, Biopharmaceutics & drug disposition.

[41]  R. Kato,et al.  The importance of substrate concentration in determining cytochromes P450 therapeutically relevant in vivo. , 1994, Pharmacogenetics.

[42]  W. Trager,et al.  Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. , 1994, The Journal of pharmacology and experimental therapeutics.

[43]  K. Chiba,et al.  The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. , 1994, British journal of clinical pharmacology.

[44]  P. Beaune,et al.  Expression of human liver cytochrome P450 IIIA4 in yeast. A functional model for the hepatic enzyme. , 1990, European journal of biochemistry.

[45]  J. Miners,et al.  Characterisation of theophylline metabolism in human liver microsomes. , 1987, British journal of clinical pharmacology.

[46]  K H Antonin,et al.  Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. , 1976, The Journal of pharmacology and experimental therapeutics.

[47]  D. Smith,et al.  Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man. , 1992, Xenobiotica; the fate of foreign compounds in biological systems.

[48]  D. Ciraulo,et al.  Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers , 1988, Clinical pharmacology and therapeutics.

[49]  S. Otton,et al.  In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver. , 1988, Drug metabolism and disposition: the biological fate of chemicals.

[50]  Beckett Ah,et al.  The distribution, metabolism and excretion of mexiletine in man. , 1977 .

[51]  T. Suzuki,et al.  Drug absorption and metabolism studies by use of portal vein infusion in the rat. II. Influence of dose and infusion rate on the bioavailability of propranolol. , 1974, Chemical & pharmaceutical bulletin.

[52]  M. Kendall,et al.  The effect of age on the pharmacokinetics of metoprolol and its metabolites. , 1981, British journal of clinical pharmacology.

[53]  M. Grant,et al.  Human adult hepatocytes in primary monolayer culture. Maintenance of mixed function oxidase and conjugation pathways of drug metabolism. , 1987, Biochemical pharmacology.

[54]  C. Libersa,et al.  Mexiletine metabolism in vitro by human liver. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[55]  R. Boyes,et al.  The tissue distribution, metabolism and excretion of lidocaine in rats, guinea pigs, dogs and man. , 1972, The Journal of pharmacology and experimental therapeutics.

[56]  G R Wilkinson,et al.  Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. , 1977, The Journal of pharmacology and experimental therapeutics.

[57]  J. Lin,et al.  Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[58]  Grant R. Wilkinson,et al.  A physiological approach to hepatic drug clearance , 1975 .

[59]  U. Meyer,et al.  Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4 , 1989, Clinical pharmacology and therapeutics.